Why this research matters
Cancer treatment is becoming more precise. At the centre of that shift are nanoparticles: engineered structures small enough to carry therapeutic molecules towards specific cells and tissues.
In this RSD conversation, Prof. João Conde considers how nanobiotechnology could improve drug delivery, how tumour heterogeneity complicates treatment and why the path from a promising laboratory result to a useful therapy requires collaboration across disciplines.
The discussion places the technology in context. Better delivery is not only an engineering challenge; it is also a question of biology, safety, access and the needs of patients.
Key takeaways
- Nanoparticles can be designed to carry treatments towards specific biological targets.
- Tumour heterogeneity remains a major challenge for precision medicine.
- Translating nanotechnology into care requires rigorous testing and cross-disciplinary work.